AstraZeneca's ZS-9 Timeline Hit By FDA Complete Response Letter
Executive Summary
A manufacturing issue at a plant in Texas has resulted in a complete response letter from the FDA, dashing AstraZeneca's hopes that its potential best-in-class treatment for hyperkalemia, ZS-9, would be approved in this year's first half – but the good news is that no new clinical data is required on the drug.
You may also be interested in...
AstraZeneca’s Lokelma Approved In US With Label Benefits Over Veltassa
After delays caused by two complete response letters, AstraZeneca’s Lokelma has been approved in the US with label benefits over its major competitor, Vifor Pharma’s Veltassa.
10 Approvals To Watch For In Early 2017
Dupixent, Austedo, brigatinib and Olumiant are among a raft of new drug approvals expected in the first four months of the year. Here, with help from Informa Pharma's Biomedtracker, we take a look at 10 of the more interesting products looking close to reaching the market, some for the second time of asking.
Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies
Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.